ProShare Advisors LLC Takes Position in Cryoport, Inc. (NASDAQ:CYRX)

ProShare Advisors LLC acquired a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,250 shares of the company’s stock, valued at approximately $95,000.

Several other hedge funds have also bought and sold shares of the business. Franklin Resources Inc. boosted its stake in Cryoport by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after acquiring an additional 1,512 shares in the last quarter. Rhumbline Advisers boosted its stake in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after acquiring an additional 1,764 shares in the last quarter. Nebula Research & Development LLC boosted its stake in Cryoport by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after acquiring an additional 2,207 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Cryoport by 8.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company’s stock worth $467,000 after buying an additional 4,902 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Cryoport by 11.6% in the fourth quarter. Invesco Ltd. now owns 51,803 shares of the company’s stock worth $403,000 after buying an additional 5,364 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on CYRX shares. UBS Group upped their target price on shares of Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. Roth Mkm reiterated a “buy” rating and issued a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th. Guggenheim reissued a “buy” rating and set a $10.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. Finally, Morgan Stanley decreased their price objective on shares of Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Monday, May 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Cryoport presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Cryoport Trading Up 8.1%

Shares of CYRX opened at $5.84 on Wednesday. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $11.64. The company has a 50-day moving average of $5.90 and a 200 day moving average of $6.73. The firm has a market capitalization of $292.80 million, a price-to-earnings ratio of -1.73 and a beta of 1.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. On average, research analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Hariri sold 12,500 shares of the company’s stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total transaction of $76,250.00. Following the transaction, the director now owns 8,061 shares of the company’s stock, valued at $49,172.10. This represents a 60.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,330 shares of company stock valued at $194,603. Insiders own 10.00% of the company’s stock.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.